As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...